Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.
The company announced that a second patient among the 55 enrolled in the trial has achieved a confirmed complete response (CR). This finding follows the announcement earlier this week of a separate patient who achieved a pathological CR in the trial.
A confirmed complete response is a formal designation of response where there is a complete disappearance of all tumour lesions that is maintained for over 2 months. This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body.
Amplia CEO and Managing Director Dr Chris Burns said, “To see a second complete response in the ACCENT trial is really wonderful news, particularly given how rare these are observed in advanced pancreatic cancer. Along with the pathological CR announced earlier in the week, this outcome further demonstrates the promising activity narmafotinib, on top of standard-of-care, is showing in pancreatic cancer.”